Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Ondine Biomedical's Steriwave added to NHS Supply Chain
(Sharecast News) - Life science company Ondine Biomedical announced on Friday that its 'Steriwave' nasal photodisinfection treatment was now available through the NHS Supply Chain. The AIM-traded firm said the development would simplify the procurement process for NHS hospitals in England and Wales, marking the first inclusion of a light-activated antimicrobial in the supply chain.
It described Steriwave as an antimicrobial treatment that quickly eliminates infection-causing pathogens without contributing to antimicrobial resistance (AMR).
The company said it was a superior alternative to the antibiotic mupirocin, which was traditionally used for nasal decolonisation to prevent healthcare-associated infections, but was associated with high rates of AMR and low patient compliance.
In March, the Mid Yorkshire Teaching NHS Trust became the first in the UK to adopt Steriwave as the standard of care for hip and knee surgery patients to prevent surgical site infections (SSIs).
The adoption at Pontefract and Pinderfields NHS Hospitals followed a successful initial deployment at Pontefract Hospital.
Ondine Biomedical said it was also collaborating with the Mid Yorkshire Teaching NHS Trust and Health Innovation Yorkshire & Humber to sponsor a health economic analysis conducted by the York Health Economics Consortium (YHEC).
The study, expected to be completed later in the year, aimed to support the wider adoption of Steriwave across the NHS and explore additional surgical applications.
"SSIs, among the most common healthcare-associated infections, affect one in 20 NHS surgical patients and cost NHS England over £2bn annually, with costs expected to rise due to increasing AMR," Ondine said in its statement.
"WHO and NICE recommend eliminating harmful pathogens from the nasal cavities before surgery as a key approach to preventing SSIs.
"Steriwave uses a proprietary photosensitive microbial stain and activating red light to destroy nasal pathogens in a single, five-minute treatment without triggering AMR."
At 1124 BST, shares in Ondine Biomedical were up 11.84% at 8.39p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
